ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn... (t candidates through clinical proof-of-c...)

HOME >> MEDICINE >> TECHNOLOGY

ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease

Date:6/12/2008

t candidates through clinical proof-of-concept, at which point GSK will have options to license certain product candidates.

"We're delighted with the progress our team has made in advancing one of our second-generation CCR9 antagonist compounds towards the clinic," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "This new compound adds to our existing clinical pipeline that already contains three other novel drug candidates, each targeting different chemokine receptors and currently in clinical trials. This growing clinical pipeline, in addition to our robust preclinical and discovery programs, clearly positions ChemoCentryx as an industry leader in chemokine-based therapeutics."

About CCX282-B (Traficet-EN(TM))

Traficet-EN is a small molecule, orally-available drug that is administered in capsule form and which controls the inappropriate immune system response underlying inflammatory bowel disease (IBD) by blocking the CCR9 chemokine receptor. In adults, CCR9 is a highly specific receptor expressed by T cells that migrate selectively to the digestive tract. The trafficking of T cells to the small and large intestine causes persistent inflammation that may result in Crohn's disease or ulcerative colitis - the two principal forms of IBD. In preclinical studies, the compound worked both therapeutically and prophylactically in models of Crohn's disease and ulcerative colitis. In addition to the ongoing PROTECT-1 clinical trial in Crohn's disease and the ongoing Phase II trial in celiac disease, ChemoCentryx has completed five Phase I clinical trials and one four-week Phase II Crohn's disease trial of Traficet-EN, demonstrating that the product candidate is well-tolerated and appropriate for once- or twice-daily oral dosing. Traficet-EN may offer advantages over existing therapeutic approaches for Crohn's disease by potentially offering reduced side effects and convenient oral dosing to patients.

About Cro
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule

Post Your Comments:

(Date:12/16/2009)... Mass., Dec. 16 Boston Scientific Corporation (NYSE: ... Board of Directors has elected Nelda Connors as a ... of the Electrical and Metal Products division of Tyco ... Eaton Corporation, holding several positions in operations and general ... in a number of executive and management capacities with ...

(Date:12/16/2009)... Mass., Dec. 16 According to Millennium ... technology market intelligence, health care reforms in China ... market in 2009, and will continue to fuel ... Asia Pacific Markets for Interventional Cardiology Devices ... the Chinese government will allow the Chinese drug-eluting ...

(Date:12/16/2009)... /PRNewswire/ -- Sanofi Pasteur, the ... today that it has entered into an ... develop and commercialize its prophylactic vaccine against ... aureus or MRSA. MRSA are responsible ... referred to as multidrug-resistant Staphylococcus aureus ...

Breaking Medicine Technology:Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 2 Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 3 Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 2 Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 3 Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 2 Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 3 Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 4 Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs Zicam Cold Remedy Nasal Gel 49143 1 Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs Zicam Cold Remedy Nasal Gel 49143 2 Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs Zicam Cold Remedy Nasal Gel 49143 3 Wisconsin Doctor Raj Ambay Elected to the AMA Board of Trustees 49142 1 Wisconsin Doctor Raj Ambay Elected to the AMA Board of Trustees 49142 2 LA County Calls for Repeal of Federal Cell Tower Health Preemption 49140 1 LA County Calls for Repeal of Federal Cell Tower Health Preemption 49140 2

[0] Boston Scientific Announces Election of Nelda Connors to Its Board of Directors [0] Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group [0] Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections

... EPOC Results Published in March 22 Issue ... March 20 Sanofi-aventis,today announced that efficacy ... Intergroup study published in the March 22 ... patients Eloxatin(R) (oxaliplatin injection) in,combination with 5-fluorouracil/leucovorin ...

... NanoBio Corporation,announced today that it has seen promising ... study of NB-002, a topical lotion for onychomycosis ... clearly,justify completing the study, according to NanoBio scientists., ... out a clear nail after,successfully treating the infection ...

Other Medicine Technology:Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 2 Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 3 Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 4 Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases 5 NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis 2

Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis

(Date:12/16/2009)... of Medicine,s (BUSM) Pulmonary Center has received a ... Lung, and Blood Institute to derive stem cells ... , Darrell Kotton, MD, associate professor of ... assistant professor of medicine, are the principal investigators ... Mostoslavsky lead a multicenter investigative team of five ...

(Date:12/16/2009)... honored to announce that Chris Wepfer and Jackie Kirby have ... Healthcare Traveler magazine’s 2009 Recruiters of the Year Showcase. This ... honors and the first for Jackie. , ... ... national healthcare staffing agency, is honored to announce that Chris ...

(Date:12/16/2009)... Medizone International, Inc. (OTC Bulletin Board: MZEI) ... the Board of Medizone New Zealand Ltd., a ... a 50% interest, agreed on December 14, 2009 ... Medizone International all global marketing rights of the ... G. Marshall said, "Time has eroded the relevance ...

(Date:12/16/2009)... finds 6- to 11-month interval lessens complication risks , , TUESDAY, ... of joy has had such a profound impact on your ... a breath. A new study suggests that you might ... again, and that more than 11 months could be even ... between pregnancies was less than six months, the chances of ...

(Date:12/16/2009)... /PRNewswire-FirstCall/ - TSO3 Inc. ("TSO3") (TSX: TOS) and ... been reached for 3M to be the exclusive ... The partnership with TSO3, an innovator in low ... settings through the use of ozone, will include ... 3M,s global sales channel. This agreement, combined with ...

Breaking Medicine News(10 mins):Health News:Boston University School of Medicine's pulmonary center receives $1.4 million grant 2 Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 2 Health News:Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients 3 Health News:Medizone International, Inc. Approves Repurchase of Global Marketing Rights 2 Health News:For Babies' Sake, Pregnancy Spacing Matters 2 Health News:For Babies' Sake, Pregnancy Spacing Matters 3 Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 2 Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 3 Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 4

[0] Boston University School of Medicine's pulmonary center receives $1.4 million grant [0] Medical Solutions is Proud to Announce Chris Wepfer and Jackie Kirby as the Company's Recruiter of the Year Recipients [0] Medizone International, Inc. Approves Repurchase of Global Marketing Rights [0] For Babies' Sake, Pregnancy Spacing Matters [0] TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received

... newly redesigned version of its consumer health information site, MayoClinic.com. The ... user,s experience. , ... Rochester, Minn. (PRWEB) March 27, ... its consumer health information site, MayoClinic.com. The updated site has many ...

... The founder of a public database that helps ... medical decisions is the 2009 recipient of the March ... the field of genetic sciences.Roberta "Bonnie" Pagon, MD, professor ... School of Medicine in Seattle, developed the Web site ...

... concentrating in areas with high doctor/patient ratios, experts say ... and urban areas of the United States may soon ... for underserved and aging populations, a new study warns. ... areas with already established medical communities, a trend that ...

... ever, a Michigan State University researcher has shown cholesterol ... causing a heart attack or stroke. , The findings ... the cardiology division in MSU,s College of Human Medicine, ... cardiovascular attacks. Abela,s findings appear in the April issue ...

... residents pleaded guilty today in connection with a $10 ... Assistant Attorney General Rita M. Glavin of the Criminal ... Southern District of Florida announced. Dr. Carmen Del Cueto, ... one count of conspiracy to commit health care fraud ...

... 26 Pregis Corporation, a leading international manufacturer, marketer, ... solutions, today announced its 2008 fourth quarter and full ... Company generated net sales of $219.6 million, a decrease ... the fourth quarter of 2007. Excluding incremental revenue ...

MayoClinic.com Releases New Design Roberta A. Pagon Receives Lifetime Award in Genetics from March of Dimes Midwest and Northeast May Face Surgeon Shortage MSU researcher links cholesterol crystals to cardiovascular attacks Miami Doctor and Chemist Plead Guilty in HIV Infusion Fraud Scheme Pregis Announces Fourth Quarter and Full Year 2008 Financial Results

... for ELISA testing. The system consists of ... Robot, and 1 Plate hotel. The Dade ... of samples from primary tubes via the ... robotic transport system and plate processing via ...

... The Genesis RMP is ideal for ... as for reference and pharmaceutical laboratories. It ... available ELISA and EIA assays from different ... annual throughput of up to 600'000 tests, ...

... IMMULITE and IMMULITE 1000 assays ... the IMMULITE and IMMULITE 1000, ... which offer simplicity in both ... can be found in a ...

... ENA Enzyme-Linked Immunosorbent Assay (ELISA) is intended for ... La, Scl-70, and Jo-1 in human sera. ... detect antibodies in a single serum specimen. ... used as an aid to the diagnosis of ...

Medicine Products:

Quadriga™ System Genesis RMP IMMULITE/IMMULITE 1000 IGFBP-3 ENA Combined Screen (6 antigens) Sm/RNP, Sm, Jo-1, Scl-70, SS-A, SS-B

ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn...(t candidates through clinical proof-of-c...),Health